Vanderbilt Research Into GlyT1 Inhibition May Result In New Approach To Treating Schizophrenia
This article was originally published in The Pink Sheet Daily
Executive Summary
Vanderbilt's Center for Neuroscience Drug Discovery licenses three preclinical GlyT1 candidates to Karuna Pharmaceuticals, one of three business development actions by the center in recent weeks.